# Vyvanse

NDC: 59417-117
Generic name: LISDEXAMFETAMINE DIMESYLATE
Labeler / Manufacturer: Takeda Pharmaceuticals America, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: TABLET, CHEWABLE
Routes: ORAL
Marketing started: 20170128

FDA application: NDA208510

## Active ingredients

- LISDEXAMFETAMINE DIMESYLATE: 30 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"59417-117"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=59417-117
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad